GMP IPO Watch
1. Today’s Big Move: The Anchor Allotment
Before the retail public gets a chance tomorrow, institutional "anchor" investors are placing their bids today, March 23.
The Goal: The company is looking to lock in a significant portion of its ₹409 crore goal from big funds today.
What to watch: If we see top-tier domestic mutual funds or global insurance players joining the anchor list, it will provide a much-needed confidence boost for the public opening tomorrow.
2. The "Sterling" Portfolio: What do they do?
Sai Parenteral's isn't just a local pharmacy supplier. They are a high-tech manufacturer of injectables (which contribute over 44% of their revenue) and other complex dosage forms like tablets and ointments.
Global Footprint: They recently acquired a majority stake in Noumed Pharmaceuticals (Australia), giving them direct access to the Australian and New Zealand markets.
Therapeutic Range: They cover everything from cardiovascular and anti-diabetic meds to neuropsychiatry and dermatology.
3. Grey Market Pulse: A "Flat" Signal
Current GMP: ₹0 (as of midday today).
Estimated Listing: ₹392 (0% gain).
Interpretation: Currently, the grey market is showing "zero" excitement. This often happens when a stock is priced "to perfection" or when the broader market (Nifty/Sensex) is under pressure. This is likely a stock for people who believe in the company's 3-year growth plan rather than those looking for a quick "listing day" flip.
4. IPO Timeline & Application Guide
| Event / Detail | Information |
|---|---|
| IPO Opens for Public | Tomorrow, Tuesday, March 24, 2026 |
| IPO Closes | Friday, March 27, 2026 |
| Price Band | ₹372 to ₹392 per share |
| Minimum Lot Size | 38 Shares |
| Retail Min. Investment | ₹14,896 |
| Listing Date | Thursday, April 2, 2026 |
5. Financial Snapshot: Growth vs. Valuation
The Growth: Revenue grew at a healthy 3-year CAGR of ~30%, with profits jumping to ₹14.45 crore in FY25.
The Valuation: At the upper price of ₹392, the company is asking for a P/E ratio of ~72x.
Peer Check: For context, peers like Innova Captab trade around 32x, while Sai Life Sciences (a larger player) trades at over 100x. Sai Parenteral's is definitely positioned as a "premium" priced issue.
6. The "Reality Check": Risks to Consider
Regulatory Red Flags: As of late 2025, the company faced two blacklisting orders from state health agencies regarding product quality. While they are contesting these in court, a negative outcome could hurt their ability to win government tenders.
Manufacturing Pause: They plan to shut down two major units in Hyderabad for ~6 months to upgrade them using IPO funds. This could lead to a temporary revenue dip of about ₹42 crore.
Customer Concentration: A massive 92% of their revenue in 2023 came from injectables alone; any shift in that market hits them hard.
